1,403
Views
2
CrossRef citations to date
0
Altmetric
Editorial

Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children

ORCID Icon, , , & ORCID Icon
Pages 241-244 | Received 21 Sep 2018, Accepted 23 Nov 2018, Published online: 06 Dec 2018

References

  • Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J Lipid Res. 2005;46(2):179–190.
  • de Ferranti SD, Newburger JW. Dyslipidemia in children: definition, screening, and diagnosis. 2017 Jun 20 [cited 2018 Sep 12]. Available from: https://www.uptodate.com/contents/dyslipidemia-in-children-definition-screening-and-diagnosis
  • Expert panel on integrated guidelines for cardiovascular H, risk reduction in C, adolescents, national heart L, blood I. expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011; 128(Suppl 5): S213–S56.
  • Brett T, Qureshi N, Gidding S, et al. Screening for familial hypercholesterolaemia in primary care: time for general practice to play its part. Atherosclerosis. 2018;277:399–406.
  • Kolovou GD, Bilianou H, Mikhailidis DP. Postprandial lipemia in children and adolescents. Curr Vasc Pharmacol. 2011;9(3):318–320.
  • Freedman DS, Mei Z, Srinivasan SR, et al. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the bogalusa heart study. J Pediatr. 2007;150(1):12–17 e2.
  • Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J. 2013;34(45):3478–90a.
  • Miller ML, Wright CC, Browne B. Lipid-lowering medications for children and adolescents. J Clin Lipidol. 2015;9(5 Suppl):S67–S76.
  • Eiland LS, Luttrell PK. Use of statins for dyslipidemia in the pediatric population. J Pediatr Pharmacol Ther. 2010;15(3):160–172.
  • Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007;27(8):1803–1810.
  • Kusters DM, Caceres M, Coll M, et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr. 2015;166(6):1377–84e1-3.
  • Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract. 2008;62(1):88–96.
  • Garcia-Rios A, Nikolic D, Perez-Martinez P, et al. LDL and HDL subfractions, dysfunctional HDL: treatment options. Curr Pharm Des. 2014;20(40):6249–6255.
  • Colletti RB, Neufeld EJ, Roff NK, et al. Niacin treatment of hypercholesterolemia in children. Pediatrics. 1993;92(1):78–82.
  • Davidson MH. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J Clin Lipidol. 2011;5(2):76–81.
  • Wiegman A, Hutten BA. Novel pharmacological treatments for children and adolescents with heterozygous familial hypercholesterolemia. Expert Rev Clin Pharmacol. 2017;10(9):919–921.
  • Cofan M, Ros E. Use of plant sterol and stanol fortified foods in clinical practice. Curr Med Chem. 2018 Jul 8. doi: 10.2174/0929867325666180709114524.
  • European Medicines Agency, Summary of opinion: Repatha (evolocumab). [cited 2018 Sep 12]. Available from: http://webcache.googleusercontent.com/search?q=cache:http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003766/WC500187093.pdf
  • Bogsrud MP, Langslet G, Wium C, et al. Treatment goal attainment in children with familial hypercholesterolemia: a cohort study of 302 children in Norway. J Clin Lipidol. 2018;12(2):375–382.
  • Joyce NR, Wellenius GA, Eaton CB, et al. Patterns and predictors of medication adherence to lipid-lowering therapy in children aged 8 to 20 years. J Clin Lipidol. 2016;10(4):824–32 e2.
  • Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425–2437.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.